Response-guided neoadjuvant chemo beneficial in breast CA

September 7, 2013
Response-guided neoadjuvant chemo beneficial in breast CA
For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.

(HealthDay)—For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.

Gunter von Minckwitz, M.D., from the Institute for Pathology in Berlin, and colleagues examined disease-free survival (DFS) and overall survival (OS) among patients with early breast cancer after treatment with response-guided neoadjuvant chemotherapy. A total of 2,072 patients were treated with two cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC). Responders were randomized to four or six additional TAC cycles (704 and 686 patients, respectively), while early non-responders were assigned to four cycles of TAC (321) or vinorelbine and capecitabine (NX; 301 patients) before surgery.

The researchers found that DFS was significantly longer for early responders assigned to eight sessions of TAC versus six sessions (hazard ratio [HR], 0.78) and in early non-responders receiving TAC-NX versus six sessions of TAC (HR, 0.59). Compared with conventional chemotherapy (six sessions of TAC), response-guided therapy (eight sessions of TAC or TAC-NX) correlated with significantly longer DFS (HR, 0.71) and OS (HR, 0.79) in exploratory analysis. In all hormone receptor-positive tumors, but not hormone receptor-negative tumors, DFS was longer after response-guided chemotherapy.

"This exploratory analysis suggests that response-guided might improve survival and is most effective in -positive tumors," the authors write. "If confirmed, the response-guided approach could provide a clinically meaningful advantage for the neoadjuvant over the adjuvant approach in early ."

Several authors disclosed to pharmaceutical companies, including Amgen, Chugai, Roche, and sanofi-aventis, all of which funded the study.

Explore further: Pathologic response prediction of survival aided by tumor type

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Pathologic response prediction of survival aided by tumor type

May 30, 2012
(HealthDay) -- Pathologic complete response (pCR) is more highly predictive of recurrence-free survival (RFS) when specific breast cancer tumor type is factored in, according to a study published online May 29 in the Journal ...

Smoking worsens outcomes with advanced colon cancer

April 6, 2013
(HealthDay)—Smoking is tied to significantly shorter disease-free survival (DFS) and time to recurrence (TTR) in patients undergoing treatment for stage III colon cancer, according to a study published April 1 in the Journal ...

Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients

August 23, 2011
Amid the controversy surrounding the Food and Drug Administration's ruling that Avastin should no longer be used to treat metastatic breast cancer, a new multinational Phase III clinical trial shows that Avastin significantly ...

Breast cancer patients who lack RB gene respond better to neoadjuvant chemotherapy

July 26, 2012
Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and the Kimmel ...

Early PET response to neoadjuvant chemo predicts increased survival in sarcoma patients

April 2, 2012
An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers ...

Recommended for you

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.